Overall, priming with KISIMA-HPV and boosting with VSV-GP-HPV not only supports induction of higher magnitude of tumor-specific CD8+ T cells, but also promotes their recruitment into the tumor and enhances their functionality compared to homologous viral vaccination. This evidence concerns the gene CD8A and neoplasm.